Title: The efficacy of leukotriene receptor antagonist on radioiodine-induced lung fibrosis

Biography:

Aylin Akbulut has completed her fellowship on Nuclear Medicine at the age of 30 years from Gazi University and she had postdoctoral studies at Geneva University, Switzerland with Prof O. Ratib. Prof Korkmaz, M.D., PhD is the founding director of Nuclear Medicine Department in University of Health Sciences, Ankara Training and Research Hospital. After her fellowship on Nuclear Medicine, she had her postdoctoral studies on radio-peptides at University of Texas MD Anderson Cancer Center, USA. She has published more than 50 papers in reputed journals and has been serving as an editorial board member of repute.

aylin0257@yahoo.com

Abstract

Objective: Radioiodine therapy (RAI) is a standard treatment for the treatment of metastases after total thyroidectomy in differentiated thyroid carcinomas.  However, the side effects of RAI are well known. Montelukast is an antagonist of the leukotriene receptor that inhibits the binding of cysteinyl leukotrienes to the CysLT1 receptor. Anti-fibrotic effect of montelukastin in induced lung fibrosis with bleomycin was evaluated. We examined the immunohistopathological effect of montelukast on in rat lungs after RAI.

Materials and methods: 30 Wistar albino rats were randomly divided into 3 groups each containing 10 rats. In Group 1 (control group) only total thyroidectomy was performed; Group 2 had RAI after total thyroidectomy; and Group 3 had total thyroidectomy and montelukast before and after RAI treatment. All rats were sacrified after 12 weeks. By immunohistochemical (IHC) methods TNF-Alpha and TGF-beta tissue expression were evaluated to determine the degree of fibrosis in the lungs.

Results: TNF-Alpha and TGF-beta tissue expression in Group 2 was significantly higher than Group 1 (p<0.01). However, no significant difference was found between Group 3 and group 1 in terms of TNF-alpha and TGF-beta tissue expression (p>0.01). TNF-alpha and TGF-beta tissue expression was significantly less observed in Group 3 compared to Group 2 (p<0.05).

Conclusion: Co-administration of montelukast significantly prevented RAI-induced immunohistopathological alterations, which can be associated with the radioprotective effects of montelukast.